NFKB1 and metabolic disease: Collectively, these data support the notion that liver-specific KDM2A deficiency may enhance inflammation in the liver, potentially through NF-κB activation, and lead to liver dysfunction, thus suggesting that KDM2A may be a promising therapeutic target for liver-related metabolic diseases.